Artal Group’s Cardiff Oncology CRDF Stock Holding History

Artal Group’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-750,000	Closed	-$1.05M	–	125
2022 Q4	$1.05M	Hold	750,000	–	–	0.06%	104
2022 Q3	$1.16M	Hold	750,000	–	–	0.06%	108
2022 Q2	$1.65M	Hold	750,000	–	–	0.09%	105
2022 Q1	$1.86M	Hold	750,000	–	–	0.08%	114
2021 Q4	$4.51M	Hold	750,000	–	–	0.13%	109
2021 Q3	$5M	Hold	750,000	–	–	0.12%	113
2021 Q2	$4.99M	Hold	750,000	–	–	0.11%	117
2021 Q1	$6.95M	Sell	750,000 -150,000	-17%	-$1.82M	0.15%	116
2020 Q4	$16.2M	Hold	900,000	–	–	0.37%	67
2020 Q3	$12.8M	Buy	+900,000	New	+$5.94M	0.42%	70

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Laurion Capital Management New York $1.07B AUM 75.73% 1-Year Est. Return

Citigroup New York $157B AUM 32.99% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $77B AUM 50.57% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group

Susquehanna International Group Bala Cynwyd, Pennsylvania $77.3B AUM 36.07% 1-Year Est. Return